| Dr Maja Babic, MD | |
|
1735 27th St, Waller Building, Suite 206, Portsmouth, OH 45662-2677 | |
| (740) 355-9240 | |
| (740) 355-9281 |
| Full Name | Dr Maja Babic |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 26 Years |
| Location | 1735 27th St, Portsmouth, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063673986 | NPI | - | NPPES |
| 2896979 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 35.091456 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that a poster authored by NeoStem-affiliated scientists will be presented in a presentation at the premier stem cell research event, the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting in San Francisco on June 17, 2010.
People with asthma are more likely to have symptoms of depression. A new study suggests these symptoms are linked to a host of other negative health risks that may lead to a worsening of asthma symptoms and an overall decline in health.
Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.
BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.
Following the tragic infections of two hospital staff and subsequent tracking of hundreds of people related to Ebola, hospitals around the country are requiring TRU-D SmartUVC, a portable automated UVC disinfection robot which accurately measures required dosage, be added to Ebola protocols.
› Verified 1 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that a poster authored by NeoStem-affiliated scientists will be presented in a presentation at the premier stem cell research event, the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting in San Francisco on June 17, 2010.
People with asthma are more likely to have symptoms of depression. A new study suggests these symptoms are linked to a host of other negative health risks that may lead to a worsening of asthma symptoms and an overall decline in health.
Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.
BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.
Following the tragic infections of two hospital staff and subsequent tracking of hundreds of people related to Ebola, hospitals around the country are requiring TRU-D SmartUVC, a portable automated UVC disinfection robot which accurately measures required dosage, be added to Ebola protocols.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maja Babic, MD 1735 27th St, Waller Building, Suite 206, Portsmouth, OH 45662-2677 Ph: (740) 355-9240 | Dr Maja Babic, MD 1735 27th St, Waller Building, Suite 206, Portsmouth, OH 45662-2677 Ph: (740) 355-9240 |
News Archive
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that a poster authored by NeoStem-affiliated scientists will be presented in a presentation at the premier stem cell research event, the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting in San Francisco on June 17, 2010.
People with asthma are more likely to have symptoms of depression. A new study suggests these symptoms are linked to a host of other negative health risks that may lead to a worsening of asthma symptoms and an overall decline in health.
Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.
BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.
Following the tragic infections of two hospital staff and subsequent tracking of hundreds of people related to Ebola, hospitals around the country are requiring TRU-D SmartUVC, a portable automated UVC disinfection robot which accurately measures required dosage, be added to Ebola protocols.
› Verified 1 days ago
Hullukunte Bylappa Shivaprasad, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 2001 Scioto Trail, Ste 200, Portsmouth, OH 45662 Phone: 740-353-8100 Fax: 740-353-8908 | |
Nadia M Chammas-aoun, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1735 27th St, Waller Building, Suite 108, Portsmouth, OH 45662 Phone: 740-356-6891 Fax: 740-354-6774 | |
Praveena Coimbatore, Infectious Disease Medicare: Medicare Enrolled Practice Location: 1805 27th St, Portsmouth, OH 45662 Phone: 740-356-8867 Fax: 740-356-6784 | |
Sriharsha Velury, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2001 Scioto Trl Ste 200, Portsmouth, OH 45662 Phone: 740-353-8100 Fax: 740-353-8908 | |
Dr. Ronald Eugene Arrick, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2001 Scioto Trl Ste 200, Portsmouth, OH 45662 Phone: 740-354-8837 Fax: 740-353-7943 | |
Dr. David Kenneth Byers, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1735 27th St Ste 309, Portsmouth, OH 45662 Phone: 740-356-6343 Fax: 740-356-6389 |